News
ICCC
9.79
-1.01%
-0.10
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
NASDAQ · 2d ago
Top Stock Reports for JPMorgan, Novartis & Qualcomm
NASDAQ · 2d ago
Immucell CEO Makes Bold Move With Significant Personal Stock Purchase
TipRanks · 5d ago
Monday 6/22 Insider Buying Report: NTST, ICCC
NASDAQ · 5d ago
ImmuCell CEO Paul te Boekhorst buys 8,000 shares for $75,960
PUBT · 6d ago
Weekly Report: what happened at ICCC last week (0615-0619)?
Weekly Report · 6d ago
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
NASDAQ · 06/18 14:26
Immucell Shareholders Approve Governance Measures at 2026 Meeting
TipRanks · 06/17 18:47
ImmuCell shareholders approve 2025 stock option, incentive plan at annual meeting
PUBT · 06/17 18:20
Weekly Report: what happened at ICCC last week (0608-0612)?
Weekly Report · 06/15 10:24
Immucell Advances First Defense Manufacturing Capacity Expansion Program
TipRanks · 06/10 21:03
Weekly Report: what happened at ICCC last week (0601-0605)?
Weekly Report · 06/08 10:20
Weekly Report: what happened at ICCC last week (0525-0529)?
Weekly Report · 06/01 10:24
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
NASDAQ · 05/25 13:45
Weekly Report: what happened at ICCC last week (0518-0522)?
Weekly Report · 05/25 10:28
Weekly Report: what happened at ICCC last week (0511-0515)?
Weekly Report · 05/18 10:28
ImmuCell Earnings Call Highlights Record Growth Push
TipRanks · 05/16 00:17
ImmuCell outlines capacity expansion plan backed by $2M settlement while focusing on First Defense
Seeking Alpha · 05/15 14:41
ImmuCell Q1 sales, profit rise on seasonal demand; to moderate mid-year
Reuters · 05/14 20:19
ImmuCell Q1 FY26 net income rises 34.2% to $1.94 million; product sales climb 28.4% to $10.36 million
PUBT · 05/14 20:13
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).